key: cord-0889964-2md6g8np
authors: Broggi, Achille; Ghosh, Sreya; Sposito, Benedetta; Spreafico, Roberto; Balzarini, Fabio; Lo Cascio, Antonino; Clementi, Nicola; De Santis, Maria; Mancini, Nicasio; Granucci, Francesca; Zanoni, Ivan
title: Type III interferons disrupt the lung epithelial barrier upon viral recognition
date: 2020-06-11
journal: Science
DOI: 10.1126/science.abc3545
sha: 92defb0bf674c38085ab4d2abdee237f0fe16e74
doc_id: 889964
cord_uid: 2md6g8np

Lower respiratory tract viral infections are a leading cause of mortality. Mounting evidence indicates that most severe cases are characterized by aberrant immune responses and do not depend on viral burden. Here, we assessed how type III interferons (IFN-λ) contribute to the pathogenesis induced by RNA viruses. We report IFN-λ is present in the lower, but not upper, airways of COVID-19 patients. In mice, we demonstrate IFN-λ produced by lung dendritic cells in response to a synthetic viral RNA induces barrier damage, causing susceptibility to lethal bacterial superinfections. These findings provide a strong rationale for rethinking the pathophysiological role of IFN-λ and its possible use in the clinical practice against endemic viruses, such as influenza virus, as well as the emerging SARS-CoV-2 viral infection.

The ability to resolve viral infections of the lung is dependent on the actions of interferons (IFNs) and inflammatory cytokines, yet their relative contributions to host defense and return to homeostasis remain undefined. In particular, type III IFNs (IFN-λ) have attracted much attention, as they operate primarily at mucosal surfaces (1) . Recent work established that, unlike other IFNs, IFN-λ signaling induces antiviral activities while simultaneously limiting the tissuedamaging functions of neutrophils (2) (3) (4) . When considered in the context of respiratory viral infections where inflammation appears to be the primary driver of lifethreatening symptoms, including the recently emerged severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 (5), the ability of IFN-λ to limit immunopathology but maintain antiviral activity is significant. Indeed, discussions on the possible use of IFN-λ against SARS-CoV-2 have begun (6) and a clinical trial (NCT04331899) has been initiated. Despite this interest in the use of IFN-λ to treat viral infections, the long-term effects IFN-λ on lung physiology remain largely overlooked. For example, during viral infections of the lung, immunopathology may predispose the host to opportunistic bacterial infections and IFN-λ impairs bacterial control during superinfections (7, 8) . It remains unresolved whether this is due to the antiinflammatory activity of IFN-λ, which reduces host resistance, or due to the capacity of IFN-λ to alter lung physiology upon a viral encounter. Indeed, superinfections represent the first cause of lethality upon influenza virus infection (9) and correlate with severity in coronavirus disease (COVID)-19 patients (10).

Mouse models of SARS, middle east respiratory syndrome (MERS) (11, 12) and influenza (1, 13) are characterized by a robust induction of type I and III IFNs. However, the involvement of these cytokines in COVID-19 is controversial (14, 15) . To directly evaluate the capacity of SARS-CoV-2 to induce IFNs, we tested naso-oropharyngeal swabs of COVID-19 patients and healthy controls, as well as the bronchoalveolar lavage fluid (BALF) of severe SARS-CoV-2-positive patients. Levels of IFN mRNAs in the upper airways of COVID-19 patients were not significantly different from healthy controls. By contrast, BALF of patients with severe disease presented elevated levels of both inflammatory cytokines as well as type I and III IFNs (Fig. 1, A to E) .

To evaluate the contribution of IFN-λ to the immunopathology driven by RNA respiratory viruses uncoupled from its effect on viral replication, we devised an experimental system in which pattern recognition receptors (PRRs) involved in viral sensing were stimulated with their cognate ligands. RNA viruses are sensed via either endosomal toll-like receptor (TLR)-3 and TLR-7 or cytoplasmic retinoic acid-inducible Type III interferons disrupt the lung epithelial barrier upon viral recognition Here, we assessed how type III interferons (IFN-λ) contribute to the pathogenesis induced by RNA viruses. We report IFN-λ is present in the lower, but not upper, airways of COVID-19 patients. In mice, we demonstrate IFN-λ produced by lung dendritic cells in response to a synthetic viral RNA induces barrier damage, causing susceptibility to lethal bacterial superinfections. These findings provide a strong rationale for rethinking the pathophysiological role of IFN-λ and its possible use in the clinical practice against endemic viruses, such as influenza virus, as well as the emerging SARS-CoV-2 viral infection. gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) (16) . We intratracheally instilled the TLR7 ligand, R848, or the synthetic analog of double-stranded RNA, polyinosine:polycytidylic acid (poly (I:C)), that stimulates both TLR3 and the RIG-I-MDA5 pathway in vivo (17) . PRRs were stimulated over the course of 6 days to elicit prolonged innate immune activation in the lung. Both ligands induced hypothermia (Fig. 1F ) and weight loss ( fig. S1A ), but only poly (I:C) compromised barrier function ( Fig. 1G and fig. S1B ). IFN mRNAs were strongly up-regulated by poly (I:C) but not R848 (Fig. 1 , H and I). By contrast, R848 treatment induced the upregulation of pro-inflammatory cytokines (i.e., Il1b) but this did not correlate with barrier function decrease ( In contrast to wild-type (WT) mice, mice deficient in IFNλ receptor 1 (Ifnlr1) expression were protected from poly (I:C)-induced morbidity and barrier damage (Fig. 2, A and B,  and fig. S4, A and B) . Ifnlr1 −/− mice superinfected with S. aureus were also protected ( Fig. 2C -F) compared to WT mice. By contrast, the absence of Ifnlr1 did not impact mRNA or protein levels of IFNs or pro-inflammatory cytokines ( fig. S4 , C to H). We next generated reciprocal bone marrow chimeras in which either the hematopoietic or the stromal compartments were defective for IFN-λ signaling. Absence of Ifnlr1 in the stromal compartment, but not in hematopoietic cells, phenocopied complete Ifnlr1 deficiency (Fig. 2, G and H, and  fig. S5 ). Furthermore, there was no difference in myeloid immune cell recruitment in Ifnlr1 −/− compared to WT mice (fig. S6, A to D) and depletion of neutrophils did not impact bacterial burden ( fig. S6E ). Thus, IFN-λ signaling in epithelial cells is necessary and sufficient to induce susceptibility to a secondary infection.

A targeted transcriptomic analysis on lung epithelial cells from mice treated with poly (I:C) revealed a potent downregulation of the IFN signature in Ifnlr1 −/− compared to WT mice (Fig. 3, A and B, fig. S7 , and data S1). This confirmed the predominant role of IFN-λ compared to type I IFNs during prolonged viral sensing in the lung. Consistent with the observed defect in barrier function, genes associated with apoptosis and the activation of the p53 pathway were enriched in WT compared to Ifnlr1 −/− epithelial cells (Fig. 3B ). By contrast, pathways involved in positive regulation of the cell cycle were enriched in Ifnlr1 −/− cells (Fig. 3C) . Accordingly, epithelial cells in Ifnlr1 −/− mice, as well as in stromal Ifnlr1 −/− chimeras, proliferated more efficiently after poly (I:C) administration, in the presence or absence of S. aureus (Fig. 3 , D to G). The most down-regulated gene in Ifnlr1 −/− epithelial cells compared to WT cells was the E3 ubiquitin-protein ligase makorin-1 (Mkrn1) (Fig. 3A and data S1 ). This protein induces p21 degradation and favors apoptosis via p53 under oxidative stress conditions and after DNA damage (hallmarks of severe viral infections) (19). Indeed, Ifnlr1 −/− epithelial cells showed elevated levels of p21 (Fig. 3, H and I) . Thus, the ability of IFN-λ to reduce tissue tolerance stems from its capacity to inhibit tissue repair by directly influencing epithelial cell proliferation and viability.

We next investigated the cellular source and molecular pathways that drive IFN-λ production. Upon poly (I:C) administration, lung-resident dendritic cells (DCs) expressed the highest levels of IFN-λ transcript, both during the early and late phases following poly (I:C) administration ( Fig. 4A  and fig. S8A ). By contrast, epithelial cells, alveolar macrophages, and monocytes expressed type I IFNs and pro-inflammatory cytokines but no IFN-λ transcripts ( fig. S8 , A to C). Depletion of CD11c + DCs was sufficient to abolish the production of IFN-λ but not type I IFNs (Fig. 4, B and C, and fig. S8 , D and E). Alveolar macrophages were not depleted under our experimental conditions ( fig. S8F ) and did not produce IFNλ (Fig. 4A) . By using in vitro-generated DCs, we found that IFN-λ was induced only when the TLR3 pathway was activated ( Fig. 4D and fig. S9, A and B) . Consistent with in vivo data, TLR7 stimulation in vitro induced only the up-regulation of pro-inflammatory cytokines (Fig. 4D and fig. S9, A and  B) . Ex vivo analysis showed that conventional (c)DC1 are the major producer of IFN-λ ( fig. S10 ). Activation of RIG-I/MDA5 via intracellular delivery of poly (I:C) (Fig. 4D and fig. S9, A and B) and of 3-phosphate-hairpin-RNA (3p-hpRNA, fig. S11 , A to E) induced high levels of type I IFNs, but not type III IFNs in a mitochondrial antiviral signaling protein (MAVS)dependent manner. Blockade of endosomal acidification via chloroquine treatment confirmed the importance of TLR3 for S12, A and B) . WT mice or mice that do not respond to TLR3 stimulation (Toll-like receptor adaptor molecule 1 deficient (Ticam1 −/− )) were treated in vivo with poly (I:C). Only DCs sorted from Ticam1 −/− mice did not express IFN-λ mRNA although they still expressed type I IFN mRNA, Fig. 4 , E and F). Furthermore, Ticam1 −/− mice were protected against S. aureus superinfections (Fig. 4G) . Ti-cam1 −/− mice also showed lower IFN-λ (but not type I IFN) mRNA levels (Fig. 4, H and I) . Similar results were obtained when only hematopoietic cells were deficient in Ticam1 (Fig.  4 , J to L).

The immune system evolved to protect against pathogens but doing so often threatens host fitness and can cause immunopathologies (20) . In COVID-19, SARS, MERS, and flu, severe symptoms and death occur late, and after the peak in viral load, indicating a central role for the immune system in driving the pathology (21-24). In our system, we isolated the effect of immune activation from resistance to lung viral infections and demonstrated that sustained IFN-λ is produced by DCs via TLR3. TLR3 detects replication intermediates from dying cells (25) and is, thus, insensitive to viral immune evasion. Thus, IFN-λ acts on lung epithelial cells and compromises lung barrier function predisposing the host to lethal secondary bacterial infections.

Previous findings suggested that IFN-λ protects against viral infections (26) and increases the barrier functions of gut epithelial cells as well as of endothelial cells (27) (28) (29) . These discrepancies can be explained by the fact that the particular cell types targeted by IFN-λ in those studies were different. Furthermore, our data support the hypothesis that the detrimental activities of IFN-λ only occur upon chronic exposure and in the presence of tissue damage. Indeed, the early administration of IFN-λ in a mouse model of COVID-19 could confer protection (30) . In conclusion, our data enjoin clinicians to carefully analyze the duration of IFN-λ administration and to take into consideration the severity of disease when IFN-λ is used as a therapeutic agent against lung viral infections. 

Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion

IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function

Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness

IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production

Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages

COVID-19 and emerging viral infections: The case for interferon lambda

Interferon Lambda Inhibits Bacterial Uptake during Influenza Superinfection

Lambda Interferon Restructures the Nasal Microbiome and Increases Susceptibility to Staphylococcus aureus Superinfection

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

Type I and III interferons disrupt lung epithelial repair during recovery from viral infection

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Innate immunity to influenza virus infection

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

Role of tissue protection in lethal respiratory viral-bacterial coinfection

Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis

Disease tolerance as a defense strategy

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study

Middle East respiratory syndrome

Virological assessment of hospitalized patients with COVID-2019

Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads

Toll-like receptor 3 promotes cross-priming to virus-infected cells

Interferon-λ orchestrates innate and adaptive mucosal immune responses

Type III IFNs Are Commonly Induced by Bacteria-Sensing TLRs and Reinforce Epithelial Barriers during Infection

Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

I:C) daily for 6 days. (A) Volcano plot of differentially expressed genes (DEGs) between WT and Ifnlr1 −/− . DEGs (P < 0.005) with a fold change >1.5 (or <−1.5) are indicated in red. Non-significant DEGs (P > 0.005) are indicated in green. (B and C) Dot plot visualization of gene set enrichment analysis (GSEA) for pathways enriched in (B) WT epithelial cells compared to Ifnlr1 −/− and (C) Ifnlr1 −/− epithelial cells compared to WT. The color of the dots represents the adjusted P-value (significance) for each enriched pathway and its size represents the percentage of genes enriched in the total gene set. (D and E) Epithelial cell proliferation was assessed as 5-ethynyl-2′-deoxyuridine (EdU) incorporation in lung epithelial cells (CD45 − CD31 − EPCAM + ) in WT and Ifnlr1 −/− mice treated as in (A to C) (D), or treated as in (A to C) and i.t. infected on day 6 with 5 × 10 7 CFU S. aureus for 12 hours (E). (F) Mean fluorescent intensity (MFI) of Ki67 in CD45 − CD31 − EPCAM + cells of WT and Ifnlr1 −/− mice treated as in (A) to (C)

Representative histogram (H) and MFI (I) are depicted. (A to C) Four mice per genotype. (D and E) Five, and (F to I) four mice per group, median and range are represented. (D to I) Representative data of three independent experiments

and E) Two-way ANOVA, (G) one-way ANOVA, (F and I), and two-tailed t test (I) were performed. First release

I:C) or saline daily for 6 days was measured on day 6. (B) CD11c-DTR mice were injected with diphtheria toxin (DTx) to deplete the CD11c + cells in vivo. Relative Ifnl2,3 mRNA (B) and IFN-λ protein levels (C) from lung homogenates were evaluated on day 6. (D) DCs differentiated from bone marrow cells in the presence of FMS-like tyrosine kinase 3 ligand (Flt3l) for 9 days (Flt3l-DCs) from WT, Ticam1 −/− , or Mavs −/− mice were treated with 50 μg/ml poly (I:C), 1 μg transfected poly (I:C) per 10 6 cells, or 50 μg/ml R848 for 3 hours. Relative Ifnl2,3 mRNA expression was evaluated by qPCR. Ifnl2,3 (E), and Ifnb1 (F) relative mRNA expression in sorted lung epithelial cells (EC), resDCs, and moDCs sorted from WT and Ticam1 −/− mice treated as in (A) was measured on day 6. (G to I) WT and Ticam1 −/− mice were treated with poly (I:C) as in (A) and subsequently i.t. infected with 5 × 10 7 CFU of S. aureus on day 6 for 12 hours. Lung bacterial burden normalized by lung weight (G), Ifnl2,3 (H), and Ifnb1 (I) relative mRNA expression were evaluated. (J and L) WT chimeric mice reconstituted with Ticam1 −/− bone marrow (Ticam1 −/− → WT) or WT bone marrow (WT → WT) were treated as in (G) to (I)

Two-way ANOVA). (G to L) (A to C, E to L) Four mice per group, median and range are depicted. (A to F) Mean ± SEM of four mice (A to